Serum vascular endothelial growth factor165 levels and uterine fibroid volume

Acta Obstetricia et Gynecologica Scandinavica

Volumn 84, Issue 4, 2005, Pages 317-321

  Chen, Da Chung ^a,b   Liu, Jah Yao ^a   Wu, Gwo Jang ^a   Ku, Chih Hung ^c   Su, Her Young ^a   Chen, Chi Huang ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b I SHOU UNIVERSITY   (Taiwan)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Hysterectomy; Nulliparous; Parous; Uterine fibroids; Vascular endothelial growth factor

Indexed keywords

UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN 165;

ADULT; ARTICLE; BODY MASS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; NULLIPARA; PARITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; UTERUS MYOMA; UTERUS WEIGHT;

ADULT; BODY MASS INDEX; FEMALE; FOLLICULAR PHASE; HUMANS; HYSTERECTOMY, VAGINAL; LEIOMYOMA; LUTEAL PHASE; MIDDLE AGED; PARITY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; UTERINE NEOPLASMS; UTERUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 16444378588     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2005.00621.x     Document Type: Article

References (33)

1. Vollenhoven BJ, Lawrence AS, Healy DL. Uterine fibroids: a clinical review. Br J Obstet Gynaecol 1990; 97: 285-98.
2. De Leo V, Morgante G. Uterine fibromas and the hormonal pattern: the therapeutic consideration. Minerva Ginecol 1996; 48: 533-8.
3. Vollenhoven BJ, Herinhton AC, Healy DL. Epidermal growth factor and transforming growth factor-beta in uterine fibroids and myometrium. Gynecol Obstet Invest 1995; 40: 120-4.
4. Van der Ven LT, Roholl PJ, Gloudemans T, Van Buul-Offers SC, Welters MJ, Bladergroen BA et al. Expression of insulin-like growth factors (IGFs), their receptors and IGF binding proteins in normal, benign and malignant smooth muscle. Br J Cancer 1997; 75: 1631-4O.
5. Anania CA, Stewart EA, Quade BJ, Hill JA, Nowak RA. Expression of fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod 1997; 3: 685-91.
6. Fayed YM, Tsibris JC, Langenberg PW, Robertson AL Jr. Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin. Lab Invest 1989; 60: 30-7.
7. Barbieri RL, Andersen J. Uterine leiomyomas: the somatic mutation theory. Semin Reprod Endocrinol 1992; 183: 795.
8. Andersen J, Barbieri RL. Abnormal gene expression in uterine leiomyomas. J Soc Gynecol Invest 1995; 2: 663-72.
9. Townsend DE, Sparkes RS, Baluda MC, McClelland G. Unicellular histogenesis of uterine leiomyomas as determined by electrophoresis of glucose-6-phosphate dehydrogenase. Am J Obstet Gynecol 1970; 107: 1168-73.
10. Casey R, Rogers PA, Vollenhoven BJ. An immunohistochemical analysis of fibroid vasculature. Hum Reprod 2000; 15: 1469-75.
11. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
12. Gentry CC, Okolo SO, Fong LF, Crow JC, Maclean AB, Perrett CW. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin Sci (Lond) 2001; 101: 691-5.
13. Agrwal R, Prelevic G, Conway G, Payne NN, Ginsburg J, Jacobs HS. Serum vascular endothelial growth factor concentrations in postmenopausal women: the effect of hormone replacement therapy. Fertil Steril 2000; 73: 56-60.
14. Torry DS, Holt VJ, Keenan JA, Harris G, Caudle MR, Torry RJ. Vascular endothelial growth factor expression in cycling human endometrium. Fertil Steril 1996; 66: 72-80.
15. Akkad A, Al-Azzawi F. Changes in serum vascular endothelial growth factor following initiation of estrogen replacement after hysterectomy and oophorectomy. Acta Obstet Gynecol Scand 2001; 80: 554-8.
16. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril 1950; 1: 3-25.
17. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
18. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-30.
19. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13: 18-32.
20. Agrawal R, Conway GS, Sladkevicius P, Payne NN, Bekir J, Campbell S et al. Serum vascular endothelial growth factor (VEGF) in the normal menstrual cycle: association with changes in ovarian and uterine Doppler blood flow. Clin Endocrinol (Oxf) 1999; 50: 101-6.
21. Brown LF, Detmar M, Tognazzi K, Abu-Jawdeh G, Iruela-Arispe ML. Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/ vascular endothelial growth factor. Lab Invest 1989; 76: 245-55.
22. Kumar H, Heer K, Lee PW, Duthie GS, MacDonald AW, Greenman J et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998; 4: 1279-85.
23. Moon HS, Kim SC, Ahn JJ, Woo BH. Concentration of vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1) in the serum of patients with cervical cancer: prediction of response. Int J Gynecol Cancer 2000; 10: 151-6.
24. Loncaster JA, Cooper RA, Logue JP, Davidson SE, Hunter RD, West CM. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix. Br J Cancer 2000; 83: 620-5.
25. Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47: 211-8.
26. Harrison-Woolrych ML, Sharkey AM, Charnock-Jones DS, Smith SK. Localization and quantification of vascular endothelial growth factor messenger ribonucleic acid in human myometrium and leiomyomata. J Clin Endocrinol Metab 1995; 80: 1853-8.
27. Marshall LM, Spiegelman D, Goldman MB, Manson JE, Colditz GA, Barbieri RL et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70: 432-9.
28. Marshall LM, Spiegelman D, Manson JE, Goldman MB, Barbieri RL, Stampfer MJ et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 1998; 9: 511-7.
29. Clark DE, Smith SK, Sharkey AM, Charnock-Jones DS. Localization of VEGF and expression of its receptors fit and KDR in human placenta throughout pregnancy. Hum Reprod 1996; 11: 1090-8.
30. Clark DE, Smith SK, Licence D, Evans AL, Charnock-Jones DS. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J Endocrinol 1998; 159: 459-67.
31. Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540-8.
32. Sugino N, Kashida S, Karube-Harada A, Takiguchi S, Kato H. Expression of vascular endothelial growth factor (VEGF) and its receptors in human endometrium throughout the menstrual cycle and in early pregnancy. Reproduction 2002; 123: 379-87.
33. Smith SK. Fibroids. In: Rainsbury PA, Viniker DA, eds. Practice guide to reproductive medicine. Carnforth UK: Parthenon Publishing Group, 1997, 395-408.